Sight Sciences (SGHT) to Release Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) will likely be posting its quarterly earnings results after the market closes on Wednesday, March 5th. Analysts expect Sight Sciences to post earnings of ($0.22) per share and revenue of $18.98 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Sight Sciences Price Performance

Shares of SGHT stock opened at $2.49 on Wednesday. Sight Sciences has a twelve month low of $2.29 and a twelve month high of $8.45. The stock has a market capitalization of $126.38 million, a price-to-earnings ratio of -2.44 and a beta of 2.52. The stock has a fifty day simple moving average of $3.06 and a two-hundred day simple moving average of $4.58. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. UBS Group lowered their target price on Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a report on Monday, January 27th. Citigroup reduced their price target on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Lake Street Capital reduced their price target on Sight Sciences from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Wednesday, January 15th. Morgan Stanley reduced their price target on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, November 11th. Finally, Piper Sandler reissued a “neutral” rating and issued a $5.50 price target (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.68.

Insider Activity at Sight Sciences

In related news, CEO Paul Badawi sold 24,819 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $2.92, for a total transaction of $72,471.48. Following the transaction, the chief executive officer now directly owns 5,676,331 shares of the company’s stock, valued at $16,574,886.52. This represents a 0.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In the last ninety days, insiders have acquired 13,000 shares of company stock valued at $50,832 and have sold 63,014 shares valued at $197,295. 28.90% of the stock is currently owned by corporate insiders.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.